Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma.
OBJECTIVE
A subset of patients with hepatocellular carcinoma (HCC) with a diameter of 10 cm or larger may benefit from hepatic resection.


METHODS
Retrospective study of a multi-institutional database.


METHODS
Five major hepatobiliary centers.


METHODS
We identified 300 patients who underwent hepatic resection for HCC 10 cm or larger.


METHODS
Clinical and pathologic data were collected, and prognostic factors were evaluated by univariate and multivariate analyses. Patient survival was stratified according to a clinical scoring system and pathologic T classification.


RESULTS
The perioperative mortality rate was 5%. At a median follow-up of 32 months, the median survival was 20.3 months, and the 5-year actuarial survival rate was 27%. Four clinical factors-alpha-fetoprotein of 1000 ng/mL or higher, multiple tumor nodules, the presence of major vascular invasion, and the presence of severe fibrosis-were significant predictors of poor survival (all P<.05). Patients were assigned a clinical score according to the following risk factors: 1, no factor; 2, one or two factors; or 3, three or four factors. On the basis of the clinical score, patients could be stratified into only 2 distinct prognostic groups: no factor (score of 1) vs 1 or more factors (score of 2 or 3) (P<.001). In contrast, when patients were stratified according to pathologic T classification, 3 distinct groups were identified: T1 vs T2 vs T3 and T4 combined (P<.001). Fifty-six percent of the patients with a clinical score of 2 and 20% of patients with a clinical score of 3 actually had T1 or T2 disease on pathologic examination.


CONCLUSIONS
Patients with large HCCs should be considered for liver resection as this treatment is associated with a 5-year survival rate exceeding 25%. Clinical predictors should not be used to exclude patients from surgical resection because these factors do not reliably predict outcome.
Pawlik
Timothy M
TM
Department of Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Poon
Ronnie T
RT
Abdalla
Eddie K
EK
Zorzi
Daria
D
Ikai
Iwao
I
Curley
Steven A
SA
Nagorney
David M
DM
Belghiti
Jacques
J
Ng
Irene Oi-Lin
IO
Yamaoka
Yoshio
Y
Lauwers
Gregory Y
GY
Vauthey
Jean-Nicolas
JN
D000206:Actuarial Analysis; D006528:Carcinoma, Hepatocellular / Q000401:mortality* / Q000601:surgery*; D016208:Databases, Factual; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000401:mortality* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000032:analysis
D000509:alpha-Fetoproteins